At the Dutch Life Sciences Conference the young start-up Innofuse won the Venture Challenge Fall 2014. Innofuse is developing a new multi-infusion system that speeds up the administration of drugs in premature babies and decreases fluctuations with more than 70 percent. This is highly important for premature babies, where fluctuation and timing of medication can have a large effect and could even result in brain damage. 

Helping patients and creating better solutions in the healthcare sector is the main motive of Brechtje Riphagen as a young entrepreneur to start Innofuse.

“I am driven by the most vulnerable and young patient, for whom this product can really improve the quality of healthcare”, says Brechtje, CEO of the company. 

Innofuse targets problems physicians experience on a daily base with drug administration to critically ill and preterm infants. Existing infusion sets inherently induce significant dosage fluctuations and long delays before drugs reach the patient. Innofuse provides a patented solution: an infusion set that guarantees stability and immediacy of drug administration. Thanks to the collaboration with UMC Utrecht, Innofuse can count on a clinical partner and a launching customer. Brechtje Riphagen:

“It is in my ambition to make Innofuse the new golden standard worldwide”.

Innofuse was one of the five teams that participated in an intensive track for Life Science start-ups organized by Topsector Life Sciences and Health. With their pitch, Innofuse convinced the expert-jury and won the Venture Challenge. The challenge is organized to stimulate and support young start-ups in the Life Sciences field. In the spring of 2015 Topsector LSH will support a new edition of the Venture Challenge. The call for this edition will soon be open. More information about can be found on the website of the Venture Challenge.